2013年　業績集

  1. Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S. Angioimmunoblastic T-cell lymphoma mice model. Leuk Res 2013; 37(1): 21-27.
  2. Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, Kume M, Hatano Y, Takahashi N, Iida S, Sawada K, Tagawa H. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLOS ONE 2013; 8(3): e56954.
  3. Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, Morita A, Akinaga S, Ueda R. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 647-650.
  4. Suzuki T, Kusumoto S, Yoshida T, Mori F, Ito A, Ri M, Ishida T, Komatsu H, Niimi A, Iida S. Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2013; 97: 540-543.
  5. Ogawa Y, Suzuki K, Sakai A, Iida S, Ogura M, Tobinai K, Matsumoto K, Terui Y, Ohashi K, Ishii M, Mukai HY, Ando K, Hotta T. A phase I/II study of bortezomib-melphalan-prednisolone (VMP) for previously untreated Japanese patients with multiple myeloma. Cancer Sci 2013; 104: 912-919.
  6. Masaki A, Ishida T, Suzuki S, Ito A, Mori F, Sato F, Narita T, Yamada T, Ri M, Kusumoto S, Komatsu H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R. Autologous tax-specific CTL therapy in a primary ATL cell-bearing NOD/Shi-scid IL-2gnull mouse model. J Immunol 2013; 191: 135-144.
  7. Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M. Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer J. 2013; Oct 4; 3:e150.
  8. Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, Ishida T, Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, Ueda R, Iida S. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res 2013; 37: 1648-1655.
  9. Nakaguchi T, Okuyama T, Uchida M, Ito Y, Komatsu H, Wada M, Akechi T. Oncology nurses’ recognition of supportive care needs and symptoms of their patients undergoing chemotherapy. Jpn J Clin Oncol. 2013; 43(4):369-76.
  10. Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, Eto T, Miyazaki Y, Hidaka M, Uike N, Miyamoto T, Tsudo M, Sakamaki H, Morishima Y, Suzuki R, Utsunomiya A, et al. Impact of GVHD on allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. . 2013; 19:1731-9. (corresponding author)
  11. Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T, Ishida T, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M. Development of a novel redirected T cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Blood. 2013 Jun 13; 121(24):4894-901.
  12. Kato H, Saito C, Ito E, Furuhashi T, Nishida E, Ishida T, Ueda R, Inagaki H, Morita A. Bath-PUVA Therapy Decreases Infiltrating CCR4-Expressing Tumor Cells and Regulatory T Cells in Patients With Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):273-80.
  13. Ogura H, Inagaki A, Wakita A. A case of myelodysplastic syndrome presenting with faggot-like cells. Int J Hematol. 2013; 97(4): 443-5.
  14. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT. Anti-leukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia, 2013 Jan; 27(1):66-74.
  15. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Look AT. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia, Br J Haematol, 2013 Apr; 161(1):117-27.
  16. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma X, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Muller M, Gray NS, Jamieson CHM, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia, Cancer Discovery. 2013 May; 3(5):564-577.
  17. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CHM, von Boehmer H, Young RA, Look AT. The TAL1 Complex Targets the FBXW7 Tumor Suppressor by Activating miR-223 in Human T-Cell Acute Lymphoblastic Leukemia, J Exp Med, 2013 Jul 29; 210(8):1545-57.
  18. Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS. Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chem Biol. 2013 Jul 19;8(7): 1423-8.